NDA 011665 · Bausch
Mestinon
Pyridostigmine Bromide · Oral
Last checked: Nov 20, 2026Latest source record: Jul 25, 2014 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1959
Jan 12, 1959
Approved uses
1
Original approval plus efficacy supplements
Registered trials
45
6 Phase 3, 6 recruiting
FAERS reports
7,620
5,403 serious, 526 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Dec 2, 2020.
INDICATION: MESTINON is useful in the treatment of myasthenia gravis.
Mechanism: ACTIONS: MESTINON inhibits the destruction of acetylcholine by cholinesterase and thereby permits freer transmission of nerve impulses across the neuromuscular junction. Pyridostigmine is an analog of neostigmine (Prostigmin), but differs from it in certain clinically significant respects; for example, pyridostigmine is characterized by a longer duration of action and fewer gastrointestinal side effects.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 12, 1959 Original approval · Type 3 - New Dosage Form
1 products under this application
- MESTINON · PYRIDOSTIGMINE BROMIDE 180MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Pyridostigmine" as an intervention, any sponsor and status, largest first.
- Pyridostigmine in Severe SARS-CoV-2 InfectionPivotal-lookingStatus unknown
Instituto Nacional de Ciencias Medicas y Nutricion Salvador ZubiranAcademic, hospital or other
NCT04343963 · 436 participants (planned) · Start Apr 4, 2020 · Primary completion Sep 30, 2020
Drug: Pyridostigmine Bromide; Placebo · For: COVID-19; SARS-CoV-2
Sites: Mexico City, Mexico
- Treatment of Orthostatic Hypotension in Autonomic FailurePivotal-lookingCompleted
Vanderbilt UniversityAcademic, hospital or other
NCT00223691 · 389 participants · Start Mar 2002 · Primary completion Jan 2017
Drug: Atomoxetine; Acarbose and 19 more · For: Autonomic Failure; Orthostatic Hypotension
Sites: Nashville, Tennessee
- The Efficacy and Safety of Leflunomide or Azathioprine Therapy in Myasthenia Gravis Patients After Expand ThymectomyPivotal-lookingCompleted
First Affiliated Hospital, Sun Yat-Sen UniversityAcademic, hospital or other
NCT01727193 · 290 participants · Start Sep 2012 · Primary completion Oct 18, 2021
Drug: Azathioprine; Leflunomide · For: Myasthenia Gravis
Sites: Guangzhou, China
- Sugammadex-Induced Clenching During Neuromuscular Blockade ReversalPivotal-lookingRecruiting
Wonkwang University HospitalAcademic, hospital or other
NCT06962007 · 240 participants (planned) · Start Jul 1, 2025 · Primary completion Sep 20, 2026
Drug: Sugammadex 1 mg/kg Group; Sugammadex 2 mg/kg Group and 2 more · For: Neuromuscular Blockade Reversal Agent; Perioperative Complications; Anesthesia, General and 3 more
Sites: Iksan, South Korea
Icahn School of Medicine at Mount SinaiAcademic, hospital or other
NCT04353778 · 215 participants · Start Aug 3, 2020 · Primary completion Mar 27, 2026
Drug: Pyridostigmine; Placebos · For: HIV; Non-HIV; Vagus Nerve Dysfunction
Sites: New York, New York
- Testing Mestinon and Exercise in FibromyalgiaPivotal-lookingCompleted
Oregon Health and Science UniversityAcademic, hospital or other
NCT00535587 · 178 participants · Start Sep 2002 · Primary completion Jun 2008
Drug: pyridostigmine; Placibo · For: Fibromyalgia
Sites: Portland, Oregon
- LIFT: Life Improvement TrialPivotal-lookingRecruiting
Brigham and Women's HospitalAcademic, hospital or other
NCT06366724 · 160 participants (planned) · Start Sep 10, 2024 · Primary completion Sep 2027
Drug: Pyridostigmine; Low-Dose Naltrexone · For: ME/CFS; Long COVID; PASC
Sites: Boston, Massachusetts
- Effect of Medical Treatment and Prognosis of Postural Orthostatic Tachycardia Syndrome (POTS)Pivotal-lookingCompleted
Seoul National University HospitalAcademic, hospital or other
NCT02171988 · 150 participants · Start Mar 2014 · Primary completion Feb 2016
Drug: Propranolol; Bisoprolol and 2 more · For: Postural Orthostatic Tachycardia Syndrome
Sites: Seoul, South Korea
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- myasthenia gravis878
- fatigue781
- drug ineffective635
- asthenia614
- off label use598
- diarrhoea565
- headache537
- dyspnoea527
- nausea480
- muscular weakness410
- fall389
- dizziness344
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 61 |
| 2005 | 65 |
| 2006 | 79 |
| 2007 | 78 |
| 2008 | 109 |
| 2009 | 114 |
| 2010 | 99 |
| 2011 | 138 |
| 2012 | 145 |
| 2013 | 121 |
| 2014 | 120 |
| 2015 | 221 |
| 2016 | 325 |
| 2017 | 311 |
| 2018 | 377 |
| 2019 | 499 |
| 2020 | 548 |
| 2021 | 438 |
| 2022 | 448 |
| 2023 | 718 |
| 2024 | 903 |
| 2025 | 951 |
| 2026 | 751 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Mestinon (Pyridostigmine Bromide)
2024 spending
$7.8M
Beneficiaries
450
2,025 claims
Per beneficiary
$17,243
$25.73 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $8,353,546 |
| 2021 | $7,349,795 |
| 2022 | $7,570,178 |
| 2023 | $7,488,212 |
| 2024 | $7,759,474 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pyridostigmine in chronic intestinal pseudo-obstruction - a systematic review.
Wilkie BD, Noori J, Johnston M, et al. · ANZ J Surg 2023 · Systematic Review
- Systematic literature review: treatment of postural orthostatic tachycardia syndrome (POTS).
Schiweck N, Langer K, Maier A, et al. · Clin Auton Res 2026 · Systematic Review
- The evidence for treatments for postural orthostatic tachycardia syndrome: a systematic review of randomized trials.
Kwok CS, Lee S, Hall M, et al. · Trends Cardiovasc Med 2025 · Systematic Review, Research Support, Non-U.S. Gov't
- Treatment for postpolio syndrome.
Koopman FS, Beelen A, Gilhus NE, et al. · Cochrane Database Syst Rev 2015 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Efficacy of Pyridostigmine in Myasthenia Gravis: A Randomized, Double-Blind, Placebo-Controlled Crossover Trial.
Remijn-Nelissen L, Bakker WR, van den Hout WB, et al. · Neurology 2026 · Randomized Controlled Trial
- Treatment for postpolio syndrome.
Koopman FS, Uegaki K, Gilhus NE, et al. · Cochrane Database Syst Rev 2011 · Meta-Analysis, Systematic Review
Sponsor: Bausch
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.